PT2974728T - Agente terapêutico para a disfunção meibomiana - Google Patents

Agente terapêutico para a disfunção meibomiana

Info

Publication number
PT2974728T
PT2974728T PT147639991T PT14763999T PT2974728T PT 2974728 T PT2974728 T PT 2974728T PT 147639991 T PT147639991 T PT 147639991T PT 14763999 T PT14763999 T PT 14763999T PT 2974728 T PT2974728 T PT 2974728T
Authority
PT
Portugal
Prior art keywords
therapeutic agent
meibomian dysfunction
meibomian
dysfunction
therapeutic
Prior art date
Application number
PT147639991T
Other languages
English (en)
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of PT2974728T publication Critical patent/PT2974728T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dispersion Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PT147639991T 2013-03-13 2014-03-12 Agente terapêutico para a disfunção meibomiana PT2974728T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2013050766 2013-03-13

Publications (1)

Publication Number Publication Date
PT2974728T true PT2974728T (pt) 2020-07-21

Family

ID=51536797

Family Applications (1)

Application Number Title Priority Date Filing Date
PT147639991T PT2974728T (pt) 2013-03-13 2014-03-12 Agente terapêutico para a disfunção meibomiana

Country Status (14)

Country Link
US (4) US20160022648A1 (pt)
EP (2) EP3689348A1 (pt)
JP (5) JP6265793B2 (pt)
KR (2) KR102285110B1 (pt)
CN (2) CN105073112B (pt)
CA (1) CA2905247C (pt)
DK (1) DK2974728T3 (pt)
ES (1) ES2799185T3 (pt)
HK (3) HK1213203A1 (pt)
PL (1) PL2974728T3 (pt)
PT (1) PT2974728T (pt)
RU (2) RU2019139886A (pt)
TW (2) TWI656874B (pt)
WO (1) WO2014142146A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8746883B2 (en) 2009-04-01 2014-06-10 Tearscience, Inc. Ocular surface interferometery (OSI) devices and systems for imaging, processing, and/or displaying an ocular tear film
US10143761B2 (en) * 2012-06-19 2018-12-04 Santen Pharmaceutical Co., Ltd. Method for changing condition of an eyelid for evaluation of an eyelid disease involving plugging of meibomian gland orifices and/or telangiectasia by administration of complete freund's adjuvant
RU2019139886A (ru) * 2013-03-13 2019-12-19 Сантен Фармасьютикал Ко., Лтд. Терапевтическое средство против дисфункции мейбомиевых желез
AU2014259619B2 (en) 2013-05-03 2019-08-22 Tearscience, Inc. Eyelid illumination systems and methods for imaging meibomian glands for meibomian gland analysis
US20180015166A1 (en) * 2015-02-02 2018-01-18 Santen Pharmaceutical Co., Ltd Polyaphrons and palpebral administration thereof
CN109999032A (zh) * 2019-04-30 2019-07-12 南昌大学 雷帕霉素在制备降眼内压的局部滴眼给药药物中的应用
JPWO2021132565A1 (pt) 2019-12-26 2021-07-01
US20230145529A1 (en) * 2020-03-31 2023-05-11 Santen Pharmaceutical Co., Ltd. Silver salt-containing ophthalmic aqueous composition filled in resin container

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA935112B (en) * 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
DE19536504C2 (de) * 1995-09-29 1999-09-23 H Meinert Verwendung fluorierter Alkane
DE19861012A1 (de) * 1998-03-18 1999-09-30 Pharm Pur Gmbh Behandlungsmittel für die Ophthalmologie
US6376517B1 (en) 1998-08-14 2002-04-23 Gpi Nil Holdings, Inc. Pipecolic acid derivatives for vision and memory disorders
US6864232B1 (en) * 1998-12-24 2005-03-08 Sucampo Ag Agent for treating visual cell function disorder
US7063857B1 (en) * 1999-04-30 2006-06-20 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
DE19938668B4 (de) * 1999-08-14 2006-01-26 Bausch & Lomb Inc. Tränenersatzmittel
US20030018044A1 (en) * 2000-02-18 2003-01-23 Peyman Gholam A. Treatment of ocular disease
CA2472341C (en) 2002-02-01 2011-06-21 Ariad Gene Therapeutics, Inc. Phosphorus-containing compounds & uses thereof
AU2003272471B2 (en) * 2002-09-18 2010-10-07 Trustees Of The University Of Pennsylvania Method of inhibiting choroidal neovascularization
JP4755981B2 (ja) * 2003-07-08 2011-08-24 ノバルティス アーゲー 骨減少の処置のための、ラパマイシンおよびラパマイシン誘導体の使用
US7083802B2 (en) * 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
JP2005068101A (ja) * 2003-08-27 2005-03-17 Nippon Tenganyaku Kenkyusho:Kk 眼瞼皮膚適用型外用剤
CN102144961A (zh) * 2003-09-18 2011-08-10 参天制药株式会社 经巩膜递送
US8541413B2 (en) * 2004-10-01 2013-09-24 Ramscor, Inc. Sustained release eye drop formulations
US8313763B2 (en) * 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
ES2314354T3 (es) * 2004-11-09 2009-03-16 Novagali Pharma S.A. Emulsion de tipo aceite en agua con baja concentracion de agente cationico y potencial zeta positivo.
JP2008532953A (ja) 2005-03-08 2008-08-21 ライフサイクル ファーマ エー/エス シロリムスおよび/またはその類縁物質を含む医薬組成物
US7867988B2 (en) * 2006-09-13 2011-01-11 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
US8088789B2 (en) * 2006-09-13 2012-01-03 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
EP2187900B1 (en) * 2007-08-16 2016-11-09 The Schepens Eye Research Institute, Inc. Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues
CA3014633C (en) * 2007-10-08 2022-05-17 Aurinia Pharmaceuticals Inc. Ophthalmic compositions comprising calcineurin inhibitors or mtor inhibitors
CA3069576A1 (en) * 2008-01-09 2009-07-16 The Schepens Eye Research Institute, Inc. Therapeutic compositions for treatment of ocular inflammatory disorders
EP2349984A1 (en) * 2008-10-17 2011-08-03 Merck & Co. Combination therapy
US20120064143A1 (en) * 2008-11-11 2012-03-15 The Board Of Regents Of The University Of Texas System Inhibition of mammalian target of rapamycin
CN102460162A (zh) * 2009-05-01 2012-05-16 俄勒冈健康科学大学 体内扩增人肝细胞的方法
JP5738292B2 (ja) * 2009-07-28 2015-06-24 ライジェル ファーマシューティカルズ, インコーポレイテッド Jak経路の阻害のための組成物および方法
EP2335735A1 (en) * 2009-12-14 2011-06-22 Novaliq GmbH Pharmaceutical composition for treatment of dry eye syndrome
US20120024177A1 (en) * 2010-07-27 2012-02-02 Alrick Vincent Warner Method of Printing Fabric-Inspired Designs On Absorbent Articles
JP5713179B2 (ja) 2010-12-28 2015-05-07 スタンレー電気株式会社 自動二輪車用プロジェクタ型ヘッドランプ
EP2696869B1 (en) * 2011-04-12 2017-08-23 Rigel Pharmaceuticals, Inc. Methods for inhibiting allograft rejection
US20130102572A1 (en) 2011-04-12 2013-04-25 Dow Pharmaceutical Sciences Methods of treating skin conditions exhibiting telangiectasia
US9931031B2 (en) * 2012-02-21 2018-04-03 Massachusetts Eye & Ear Infirmary Meibomian gland dysfunction
WO2013126602A1 (en) 2012-02-21 2013-08-29 Massachusetts Eye & Ear Infirmary Inflammatory eye disorders
JP2012137778A (ja) 2012-03-19 2012-07-19 Az Electronic Materials Ip Ltd ケイ素含有微細パターン形成用組成物
US8765725B2 (en) 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
US20150125394A1 (en) 2012-06-19 2015-05-07 Santen Pharmaceutical Co., Ltd. Method for changing condition of eyelid of hairless animal
US10143761B2 (en) 2012-06-19 2018-12-04 Santen Pharmaceutical Co., Ltd. Method for changing condition of an eyelid for evaluation of an eyelid disease involving plugging of meibomian gland orifices and/or telangiectasia by administration of complete freund's adjuvant
AU2013314303B2 (en) * 2012-09-12 2018-01-18 Novaliq Gmbh Semifluorinated alkane compositions
RU2019139886A (ru) 2013-03-13 2019-12-19 Сантен Фармасьютикал Ко., Лтд. Терапевтическое средство против дисфункции мейбомиевых желез

Also Published As

Publication number Publication date
TWI623313B (zh) 2018-05-11
US11612590B2 (en) 2023-03-28
WO2014142146A1 (ja) 2014-09-18
KR102285110B1 (ko) 2021-08-02
CN107823202A (zh) 2018-03-23
DK2974728T3 (da) 2020-07-20
JP2014198709A (ja) 2014-10-23
EP2974728A4 (en) 2016-10-26
TW201825091A (zh) 2018-07-16
JP2019108383A (ja) 2019-07-04
KR102175622B1 (ko) 2020-11-06
KR20200119903A (ko) 2020-10-20
CA2905247C (en) 2021-02-16
TW201513859A (zh) 2015-04-16
JP6265793B2 (ja) 2018-01-24
JP2018065857A (ja) 2018-04-26
HK1213203A1 (zh) 2016-06-30
JP2022116182A (ja) 2022-08-09
EP2974728B1 (en) 2020-05-06
HK1245680A1 (zh) 2018-08-31
EP2974728A1 (en) 2016-01-20
PL2974728T3 (pl) 2020-10-19
US20180021314A1 (en) 2018-01-25
CN105073112B (zh) 2017-12-29
US20160022648A1 (en) 2016-01-28
CA2905247A1 (en) 2014-09-18
KR20150126345A (ko) 2015-11-11
CN105073112A (zh) 2015-11-18
RU2019139886A (ru) 2019-12-19
JP2020203927A (ja) 2020-12-24
RU2709542C2 (ru) 2019-12-18
US11951098B2 (en) 2024-04-09
US20230190716A1 (en) 2023-06-22
EP3689348A1 (en) 2020-08-05
ES2799185T3 (es) 2020-12-15
JP6495427B2 (ja) 2019-04-03
CN107823202B (zh) 2021-04-06
HK1217445A1 (zh) 2017-01-13
TWI656874B (zh) 2019-04-21
JP7082162B2 (ja) 2022-06-07
RU2015143511A (ru) 2017-04-20
US20190255026A1 (en) 2019-08-22

Similar Documents

Publication Publication Date Title
GB201321746D0 (en) Therapeutic agents
GB201321743D0 (en) Therapeutic agents
GB201321738D0 (en) Therapeutic Agents
GB201321736D0 (en) Therapeutic agents
GB201321729D0 (en) Therapeutic agents
GB201321733D0 (en) Therapeutic agents
GB201321728D0 (en) Therapeutic agents
GB201321739D0 (en) Therapeutic agents
GB201321730D0 (en) Therapeutic agents
GB201321741D0 (en) Therapeutic agents
GB201321740D0 (en) Therapeutic agents
GB201321732D0 (en) Therapeutic agents
GB201321734D0 (en) Therapeutic Agents
GB201321737D0 (en) Therapeutic Agents
HK1245680A1 (zh) 瞼板腺功能障礙的治療劑
GB201321744D0 (en) Therapeutic agents
GB201321742D0 (en) Therapeutic agents
EP3015107A4 (en) METHOD FOR TREATING MIBROMED DYNAMIC FUNCTION
GB201321735D0 (en) Therapeutic Agents
GB201321745D0 (en) Therapeutic agents
GB201321731D0 (en) Therapeutic agents
GB201321748D0 (en) Therapeutic agents
HK1223853A1 (zh) 骨質疏鬆症治療劑
GB201321749D0 (en) Therapeutic agents
EP2948129A4 (en) THERAPEUTIC COMPOUNDS